A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region
Lassa virus (LASV), the causative agent of Lassa fever, infects several hundred thousand people in Western Africa, resulting in many lethal Lassa fever cases. No U.S. Food and Drug Administration-licensed countermeasures are available to prevent or treat LASV infection. We describe the generation of...
Main Authors: | Yingyun Cai, Masaharu Iwasaki, Daisuke Motooka, David X. Liu, Shuiqing Yu, Kurt Cooper, Randy Hart, Ricky Adams, Tracey Burdette, Elena N. Postnikova, Jonathan Kurtz, Marisa St. Claire, Chengjin Ye, Jens H. Kuhn, Luis Martínez-Sobrido, Juan Carlos de la Torre |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2020-03-01
|
Series: | mBio |
Subjects: | |
Online Access: | https://doi.org/10.1128/mBio.00186-20 |
Similar Items
-
A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene
by: Yingyun Cai, et al.
Published: (2020-02-01) -
Recombinant Lassa Virus Expressing Green Fluorescent Protein as a Tool for High-Throughput Drug Screens and Neutralizing Antibody Assays
by: Yíngyún Caì, et al.
Published: (2018-11-01) -
Lassa virus: characterization of infectious agent, biological models for pathogenesis studies and variants of vaccine
by: E. I. Kazachinskaya, et al.
Published: (2021-03-01) -
Lassa Fever: Viral Replication, Disease Pathogenesis, and Host Immune Modulations
by: Hinh Ly
Published: (2020-06-01) -
Virus–Host Interactions Involved in Lassa Virus Entry and Genome Replication
by: María Eugenia Loureiro, et al.
Published: (2019-01-01)